Literature DB >> 35897079

Correction to: Psoralen alleviates radiation-induced bone injury by rescuing skeletal stem cell stemness through AKT mediated up-regulation of GSK-3β and NRF2.

Bo-Feng Yin1,2, Zhi-Ling Li1,2, Zi-Qiao Yan1,2,3, Zheng Guo1,2,3,4, Jia-Wu Liang1,2,3,4, Qian Wang1,2,3,4, Zhi-Dong Zhao1,2,3,4, Pei-Lin Li1,2, Rui-Cong Hao1,2,5, Meng-Yue Han1,2,5, Xiao-Tong Li1,2, Ning Mao6, Li Ding7,8, Da-Fu Chen9, Yue Gao10, Heng Zhu11,12,13,14.   

Abstract

Entities:  

Year:  2022        PMID: 35897079      PMCID: PMC9327291          DOI: 10.1186/s13287-022-03081-x

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN: 1757-6512            Impact factor:   8.079


× No keyword cloud information.

Correction to: Stem Cell Research & Therapy (2022) 13:241 10.1186/s13287-022-02911-2

Following publication of the original article [1], the authors have identified that the incorrect image of micro-CT scanning for normal group in Fig. 1a was included due to an error during figure preparation. The corrected image of micro-CT scanning for normal group has been updated in Fig. 1a. Therefore, the revised Fig. 1 is given in this article.
Fig. 1

Psoralen mitigated irradiation-induced osteoporosis in a murine model. For the prevention/treatment group, C57BL/6 N mice (n = 5 per group) were administered psoralen (20 mg/Kg) intragastrically every day for 1 week before/after radiation and killed 1 week after radiation. The representative MicroCT data of femur bones at week 1 post-irradiation are shown in a and b. The results of BV/TV, Tb.Sp, Tb.Th, and Tb.N demonstrated that irradiation induced significant destruction of the bone structures, while treatment or prevention with psoralen remarkably alleviated the bone injuries (a and b). In addition, the image of calcein double-labeling analysis and quantitative data of BFR and MAR showed that gastric administration of psoralen promoted new bone formation in irradiated mice (c and d). The HE staining data further demonstrated that psoralen treatment provided protective effects on the bone structures of irradiated mice (e). The ELISA data showed that psoralen treatment reduces the TRAP level in serum of irradiated mice (f). Gene expression analysis of TRAF6 and OCN in femurs also suggested that psoralen inhibited osteoclastogenesis while favoring osteogenesis in irradiated mice (g). Further pathological analysis showed that psoralen partially restored the irradiation induced the reduction of OCN-labeled OBs and the increase of TRAP-labeled OCs in the irradiated mice (h and i). All data are shown as the mean ± SD. **P < 0.01, *P < 0.05. The scale bars represent 2 mm (a and c), 500 μm (e), and 200 μm (h), respectively. IR: irradiation; BV/TV: bone volume per tissue volume; Tb.N: trabecular bone number; Tb.Sp: trabecular separation; Tb.Th: trabecular bone thickness; BFR: bone formation rate; MAR: mineral deposition rate; TRAP: tartrate-resistant acid phosphatase; OCN: osteocalcin; TRAF6: TNF receptor-associated factor 6; Ob.S/B.S: osteoblast surface per bone surface; Ob.N/B.Pm: number of osteoblasts per bone perimeter; Oc.S/B.S: osteoclast surface per bone surface; and Oc.N/B.Pm: number of osteoclasts per bone perimeter

Psoralen mitigated irradiation-induced osteoporosis in a murine model. For the prevention/treatment group, C57BL/6 N mice (n = 5 per group) were administered psoralen (20 mg/Kg) intragastrically every day for 1 week before/after radiation and killed 1 week after radiation. The representative MicroCT data of femur bones at week 1 post-irradiation are shown in a and b. The results of BV/TV, Tb.Sp, Tb.Th, and Tb.N demonstrated that irradiation induced significant destruction of the bone structures, while treatment or prevention with psoralen remarkably alleviated the bone injuries (a and b). In addition, the image of calcein double-labeling analysis and quantitative data of BFR and MAR showed that gastric administration of psoralen promoted new bone formation in irradiated mice (c and d). The HE staining data further demonstrated that psoralen treatment provided protective effects on the bone structures of irradiated mice (e). The ELISA data showed that psoralen treatment reduces the TRAP level in serum of irradiated mice (f). Gene expression analysis of TRAF6 and OCN in femurs also suggested that psoralen inhibited osteoclastogenesis while favoring osteogenesis in irradiated mice (g). Further pathological analysis showed that psoralen partially restored the irradiation induced the reduction of OCN-labeled OBs and the increase of TRAP-labeled OCs in the irradiated mice (h and i). All data are shown as the mean ± SD. **P < 0.01, *P < 0.05. The scale bars represent 2 mm (a and c), 500 μm (e), and 200 μm (h), respectively. IR: irradiation; BV/TV: bone volume per tissue volume; Tb.N: trabecular bone number; Tb.Sp: trabecular separation; Tb.Th: trabecular bone thickness; BFR: bone formation rate; MAR: mineral deposition rate; TRAP: tartrate-resistant acid phosphatase; OCN: osteocalcin; TRAF6: TNF receptor-associated factor 6; Ob.S/B.S: osteoblast surface per bone surface; Ob.N/B.Pm: number of osteoblasts per bone perimeter; Oc.S/B.S: osteoclast surface per bone surface; and Oc.N/B.Pm: number of osteoclasts per bone perimeter
  1 in total

1.  Psoralen alleviates radiation-induced bone injury by rescuing skeletal stem cell stemness through AKT-mediated upregulation of GSK-3β and NRF2.

Authors:  Bo-Feng Yin; Zhi-Ling Li; Zi-Qiao Yan; Zheng Guo; Jia-Wu Liang; Qian Wang; Zhi-Dong Zhao; Pei-Lin Li; Rui-Cong Hao; Meng-Yue Han; Xiao-Tong Li; Ning Mao; Li Ding; Da-Fu Chen; Yue Gao; Heng Zhu
Journal:  Stem Cell Res Ther       Date:  2022-06-07       Impact factor: 8.079

  1 in total
  1 in total

Review 1.  Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation.

Authors:  Peter Gál; Jan Brábek; Michal Holub; Milan Jakubek; Aleksi Šedo; Lukáš Lacina; Karolína Strnadová; Petr Dubový; Helena Hornychová; Aleš Ryška; Karel Smetana
Journal:  Histochem Cell Biol       Date:  2022-07-22       Impact factor: 2.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.